Nosocomial pneumonia, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), is a common type of hospital-acquired infection, with mortality rates estimated to be as high as 50%.

Ceftolozane/tazobactam (C/T)—a combination of ceftolozane, a potent antipseudomonal cephalosporin, and tazobactam, a beta-lactamase inhibitor—is approved for the treatment of complicated intra-abdominal infections (cIAI); complicated urinary tract infections (cUTI), including pyelonephritis; and HAP, including VAP, in the European Union and United States.

Both ceftolozane and tazobactam are eliminated renally; therefore dose adjustment is necessary based on renal function.

The efficacy and safety of C/T for the treatment of HAP/VAP was demonstrated with a C/T 3 g (ceftolozane 2 g/tazobactam 1 g) dose by 1-hour infusion every 8 hours dosing regimen in the phase 3, randomized, controlled, double-blind ASPECT-NP study; however, patients with end-stage renal disease (ESRD) requiring hemodialysis were excluded from the study.

Presented at: the 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); April 18-21 2020; Virtual.

By: Feng HP, Yogesh T Patel, Zhang Z, Jill Fiedler-Kelly, Bruno CJ, Rhee E, De Anda C, Gao W.